LACTIPLANTIBACILLUS PLANTARUM STRAIN FOR ALLEVIATING HYPERURICEMIA AND COMBINATION AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 3, 2025
app pub date -
Dec 5, 2023
filing date -
Dec 5, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure provides a Lactiplantibacillus plantarum strain for alleviating hyperuricemia and a combination and use thereof, and belongs to the technical field of microorganisms. The Lactiplantibacillus plantarum strain was deposited in the China Center for Type Culture Collection (CCTCC), Wuhan, China on Oct. 19, 2022, with an accession number of CCTCC NO: M20221596. The combination includes the Lactiplantibacillus plantarum strain BL-17, 0.01 wt % of a galacto-oligosaccharide, 0.01 wt % of an adenylic acid, and the balance of a sterilized skimmed milk solution. The combination according to the present disclosure can effectively alleviate the high serum uric acid levels in hyperuricemic rats, increase the urine uric acid levels in hyperuricemic rats, reduce the serum creatinine levels in hyperuricemic rats, reduce the serum urea nitrogen levels in hyperuricemic rats, and inhibit the activity of xanthine oxidase (XOD) in the serum and liver of hyperuricemic rats, and has an effect for alleviating hyperuricemia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully